Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

Article info

Extended reports

K Hyrich Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester M13 9PT, UK PubMed articles Google scholar articles
D Symmons Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester M13 9PT, UK PubMed articles Google scholar articles
K Watson Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester M13 9PT, UK PubMed articles Google scholar articles
A Silman Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester M13 9PT, UK PubMed articles Google scholar articles
BSRBR Control Centre Consortium
Google scholar articles
Members of BSRBR Control Centre Consortium (see the appendix) Google scholar articles

Other Contributors

Correspondence to:
Professor A Silman
ARC Unit, University of Manchester, Manchester, UK; a.silman{at}manchester.ac.uk

Citation

Hyrich K, Symmons D, Watson K on behalf of the British Society for Rheumatology Biologics Register, et al

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

Annals of the Rheumatic Diseases 2006;65:895-898.

Online issue publication

January 09, 2022